Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

NCT04884191 is registered in ClinicalTrials.gov with CTI BioPharma as lead sponsor.

NCT NCT04884191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04884191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
Lead sponsor
CTI BioPharma
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2017
Completion date
September 4, 2019
Enrollment
165 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

post- essential thrombocythemia myelofibrosis, post-polycythemia vera myelofibrosis, primary myelofibrosis